Brain and Behavior Influences on Obesity Development From Infancy Through Childhood
Johns Hopkins University · with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Rhode Island Hospital · NCT06861868
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 7–12 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 210
- US sites recruiting
- 1
- Study start
- December 2, 2024
- Record last updated
- May 7, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The investigators project, RESONATE, aims to investigate why some children develop obesity. To do this it uses data on eating and eating-related behaviors, genetic and environmental factors, and brain structure and function. This data is collected in a sub-sample of RESONANCE, a large study of families of children from infancy through childhood. The results will lay foundations for the development of early interventions to prevent or treat obesity.
Being studied: fMRI cue reactivity task; fMRI go no go task; Ad libitum meal test; Eating in the absence of hunger test
Conditions: Obesity and Overweight
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Participants from the RESONANCE cohort are eligible if the participant will reach 7-12 years of age during the proposed project period and have no food allergies.
Exclusion Criteria
- Exclusion criteria for RESONANCE include:
- In utero exposure to alcohol, cigarette, or illicit substances;
- First trimester fetal US abnormalities;
- Complicated pregnancy (e.g., pre-eclampsia);
- Complicated delivery, including APGAR scores less than 8 and/or neonatal intensive care unit (NICU) admission;
- History of neurological (e.g., epilepsy), psychiatric (e.g., anxiety or depression requiring treatment with medication) or developmental disorder (e.g., autism spectrum disorder (ASD), dyslexia);
- Contraindications for MRI including metal in the body, claustrophobia.
Recruiting US locations
Rhode Island Hospital
Providence, RI 02903
Site contact: Viren D'Sa, MD · 312-371-4178 · viren_dsa@brown.edu
Study contacts (from the official record)
- Susan Carnell, PhD · 410-955-7192 · susan.carnell@jhmi.edu
- Viren D'Sa, MD · 312-371-4178 · viren_dsa@brown.edu
Similar studies in Rhode Island
All weight loss studies in Rhode Island →- RecruitingPhase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Eli Lilly and Company
- Location
- Providence, RI + 36 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Eli Lilly and Company
- Location
- Providence, RI + 34 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
Amgen
- Location
- East Greenwich, RI + 30 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Amgen
- Location
- East Greenwich, RI + 69 other US sites
- Eligibility basics
- Ages 18–99